Evidence map›Paper›PMID 34127048›Full record

ArticleCritical care (London, England)2021

Serum uric acid, disease severity and outcomes in COVID-19.

Inès Dufour, Alexis Werion, Leila Belkhir, Anastazja Wisniewska, Marie Perrot, Julien De Greef, Gregory Schmit, Jean Cyr Yombi, Xavier Wittebole, Pierre-François Laterre and 4 more

Open access · goldAbstract read
In one paragraph

Article in Critical care (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Expression ofFuture virology · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. U-shaped association between abnormal serum uric acid levels and COVID-19 severity: reports from the Japan COVID-19 Task Force.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Inès Dufour *Division of Nephrology, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium.
Alexis Werion *Division of Nephrology, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium.
Leila BelkhirDivision of Infectious Diseases, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Anastazja WisniewskaDivision of Nephrology, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium.
Marie PerrotDivision of Nephrology, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium.
Julien De GreefDivision of Infectious Diseases, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Gregory SchmitDepartment of Pathology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Jean Cyr YombiDivision of Infectious Diseases, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Xavier WitteboleDepartment of Intensive Care Medicine, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium.
Pierre-François LaterreDepartment of Intensive Care Medicine, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium.
Michel JadoulDivision of Nephrology, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium.
Ludovic GérardDepartment of Intensive Care Medicine, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium. ludovic.gerard@uclouvain.be.
Johann MorelleDivision of Nephrology, Cliniques universitaires Saint-Luc, 1200, Brussels, Belgium. johann.morelle@uclouvain.be.ORCID 0000-0002-6925-1989
CUSL COVID-19 Research Group
Cliniques Universitaires Saint-Luc · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe severity of coronavirus disease 2019 (COVID-19) is highly variable between individuals, ranging from asymptomatic infection to critical disease with acute respiratory distress syndrome requiring mechanical ventilation. Such variability stresses the need for novel biomarkers associated with disease outcome. As SARS-CoV-2 infection causes a kidney proximal tubule dysfunction with urinary loss of uric acid, we hypothesized that low serum levels of uric acid (hypouricemia) may be associated with severity and outcome of COVID-19.

methodsIn a retrospective study using two independent cohorts, we investigated and validated the prevalence, kinetics and clinical correlates of hypouricemia among patients hospitalized with COVID-19 to a large academic hospital in Brussels, Belgium. Survival analyses using Cox regression and a competing risk approach assessed the time to mechanical ventilation and/or death. Confocal microscopy assessed the expression of urate transporter URAT1 in kidney proximal tubule cells from patients who died from COVID-19.

resultsThe discovery and validation cohorts included 192 and 325 patients hospitalized with COVID-19, respectively. Out of the 517 patients, 274 (53%) had severe and 92 (18%) critical COVID-19. In both cohorts, the prevalence of hypouricemia increased from 6% upon admission to 20% within the first days of hospitalization for COVID-19, contrasting with a very rare occurrence (< 1%) before hospitalization for COVID-19. During a median (interquartile range) follow-up of 148 days (50-168), 61 (12%) patients required mechanical ventilation and 93 (18%) died. In both cohorts considered separately and in pooled analyses, low serum levels of uric acid were strongly associated with disease severity (linear trend, P < 0.001) and with progression to death and respiratory failure requiring mechanical ventilation in Cox (adjusted hazard ratio 5.3, 95% confidence interval 3.6-7.8, P < 0.001) or competing risks (adjusted hazard ratio 20.8, 95% confidence interval 10.4-41.4, P < 0.001) models. At the structural level, kidneys from patients with COVID-19 showed a major reduction in urate transporter URAT1 expression in the brush border of proximal tubules.

conclusionsAmong patients with COVID-19 requiring hospitalization, low serum levels of uric acid are common and associate with disease severity and with progression to respiratory failure requiring invasive mechanical ventilation.

Indexed as

Severity of Illness IndexAgedBelgiumCohort StudiesCOVID-19Critical IllnessHumansKidney Tubules, ProximalMaleMiddle AgedOrganic Anion TransportersOrganic Cation Transport ProteinsOutcome Assessment, Health CareRetrospective StudiesUric AcidOrganic Anion TransportersOrganic Cation Transport ProteinsSLC22A12 protein, humanUric AcidAcute respiratory distress syndromeHypouricemiaMechanical ventilationProximal tubuleSARS-CoV-2

Identifiers

PMID34127048
PMCPMC8201458
OpenAlexW3171120066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.